Team Consulting, a medical device development firm, is introducing a new inhaler technology that may improve current therapies and even allow some new and existing drugs to be inhaled instead of being ingested. The Occoris inhaler has an active dry powder aerosolisation system that doesn’t rely on the patient’s breath for power, resulting in consistent dosing regardless of patient’s strength.
The company reports that its technology “can achieve a Fine Particle Fraction (FPF1) of 73%. This compares to an FPF of 20 to 40% for existing DPIs [dry powder inhalers].” Moreover, Team Consulting claims that, once fully developed and commercialized, single use inhalers will be able to be manufactured for around 20 cents.
Here’s a video about the Occoris inhaler technology:
Team Consulting report on the technology: Let’s make inhalers better…